Know Cancer

or
forgot password

Pilot Study of Thrombophilic States in Newly Diagnosed Patients With High-Grade Gliomas


N/A
18 Years
N/A
Not Enrolling
Both
Brain and Central Nervous System Tumors, Thromboembolism

Thank you

Trial Information

Pilot Study of Thrombophilic States in Newly Diagnosed Patients With High-Grade Gliomas


OBJECTIVES:

Primary

- Determine the overall hazard rate of first venous thromboembolism per person-year of
follow-up in patients undergoing antineoplastic therapy for newly diagnosed high-grade
gliomas.

- Correlate ABO blood type with incidence of venous thromboembolism in these patients.

- Correlate factor VIII level with incidence of venous thromboembolism in these patients.

Secondary

- Determine the overall and individual incidence rate of thromboembolism in these
patients.

- Correlate clinical variables, such as type of antineoplastic treatments, Karnofsky
performance status, and type of tumor, with incidence of venous thromboembolism in
these patients.

- Correlate demographic factors, such as age, with incidence of venous thromboembolism in
these patients.

OUTLINE: This is a pilot, multicenter study.

Patients undergo blood collection for blood typing (if not already obtained) and factor VIII
and C-reactive protein levels at baseline. Patients are followed to obtain information on
their Karnofsky performance status, treatment they receive for their brain tumor, and
occurrence of any thrombotic events (e.g., pulmonary embolism or deep-vein thrombosis).
Patients are followed every 28 days until the development of thrombotic events, after which
they are followed every 2 months for survival.

PROJECTED ACCRUAL: A total of 107 patients will be accrued for this study.

Inclusion Criteria


DISEASE CHARACTERISTICS:

- Histologically confirmed newly diagnosed malignant brain tumor

- Supratentorial grade III or IV astrocytoma of 1 of the following types:

- Anaplastic astrocytoma

- Anaplastic oligodendroglioma

- Glioblastoma multiforme

- No prior thrombotic event

PATIENT CHARACTERISTICS:

Performance status

- Karnofsky 60-100%

Life expectancy

- Not specified

Hematopoietic

- Not specified

Hepatic

- Not specified

Renal

- Not specified

PRIOR CONCURRENT THERAPY:

Biologic therapy

- No prior immunotherapy or biologic agents, including immunotoxins, immunoconjugates,
antisense therapy, peptide-receptor antagonists, interferons, interleukins,
tumor-infiltrating lymphocytes, lymphocyte-activated killer cells, or gene therapy,
for the brain tumor

Chemotherapy

- No prior chemotherapy for the brain tumor except polifeprosan 20 with carmustine
implant (Gliadel wafer)

Endocrine therapy

- No prior hormonal therapy for the brain tumor except glucocorticoids

Radiotherapy

- No prior radiotherapy for the brain tumor

- No prior cranial irradiation

Other

- No concurrent chronic anticoagulation therapy

Type of Study:

Observational

Study Design:

Observational Model: Case Control, Time Perspective: Prospective

Outcome Measure:

Thrombosis-free survival as assessed by objectively documented deep vein thrombosis or pulmonary embolism

Outcome Time Frame:

until dvt or death

Safety Issue:

Yes

Principal Investigator

Michael B. Streiff, MD

Investigator Role:

Study Chair

Investigator Affiliation:

Sidney Kimmel Comprehensive Cancer Center

Authority:

United States: Federal Government

Study ID:

NABTT-0307 CDR0000441111

NCT ID:

NCT00253669

Start Date:

April 2005

Completion Date:

August 2009

Related Keywords:

  • Brain and Central Nervous System Tumors
  • Thromboembolism
  • thromboembolism
  • adult anaplastic astrocytoma
  • adult anaplastic oligodendroglioma
  • adult glioblastoma
  • adult giant cell glioblastoma
  • adult gliosarcoma
  • Nervous System Neoplasms
  • Thromboembolism
  • Central Nervous System Neoplasms

Name

Location

Abramson Cancer Center of the University of Pennsylvania Philadelphia, Pennsylvania  19104-4283
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Baltimore, Maryland  21231-2410
Cleveland Clinic Taussig Cancer Center Cleveland, Ohio  44195
Josephine Ford Cancer Center at Henry Ford Hospital Detroit, Michigan  48202
Winship Cancer Institute of Emory University Atlanta, Georgia  30322
Wake Forest University Comprehensive Cancer Center Winston-Salem, North Carolina  27157-1096
Massachusetts General Hospital Boston, Massachusetts  02114-2617
H. Lee Moffitt Cancer Center and Research Institute at University of South Florida Tampa, Florida  33612
Lurleen Wallace Comprehensive Cancer at University of Alabama - Birmingham Birmingham, Alabama  35294